Search This Blog

Thursday, January 31, 2019

Corcept sees Q4 revenue below consensus

On a preliminary basis, Corcept Therapeutics (NASDAQ:CORT) expects a 25% jump in Q4 revenue to $66.8M, below consensus of $70.4M.
2018 revenue will be up 58% to $251.2M, also shy of consensus of $254.8M.
2019 guidance: Revenue: $285M – 315M.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)